EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Adenoviral Vector-Based Vaccine Platform for COVID-19: Current Status

Vivek P Chavda iD, Rajashri Bezbaruah, Disha Valu, Bindra Patel, Anup Kumar iD, Sanjay Prasad, Bibhuti Bhusan Kakoti, Ajeet Kaushik iD, Mariya Jesawadawala

Vaccines · 13.02.2023 · 11 (2) · 432

DOI: 10.3390/vaccines11020432 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Vaccines, online erschienen am 13.02.2023. Verfasst von Vivek P Chavda und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutics and Pharmaceutical Technology, L. M. College of Pharmacy, Ahmedabad 380009, Gujarat, India. Die Arbeit wurde bisher 80-mal zitiert (Crossref) und nennt 210 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The coronavirus disease (COVID-19) breakout had an unimaginable worldwide effect in the 21st century, claiming millions of lives and putting a huge burden on the global economy. The potential developments in vaccine technologies following the determination of the genetic sequence of SARS-CoV-2 and the increasing global efforts to bring potential vaccines and therapeutics into the market for emergency use have provided a small bright spot to this tragic event. Several intriguing vaccine candidates have been developed using recombinant technology, genetic engineering, and other vaccine development technologies. In the last decade, a vast amount of the vaccine development process has diversified towards the usage of viral vector-based vaccines. The immune response elicited by such vaccines is comparatively higher than other approved vaccine candidates that require a booster dose to provide sufficient immune protection. The non-replicating adenoviral vectors are promising vaccine carriers for infectious diseases due to better yield, cGMP-friendly manufacturing processes, safety, better efficacy, manageable shipping, and storage procedures. As of April 2022, the WHO has approved a total of 10 vaccines around the world for COVID-19 (33 vaccines approved by at least one country), among which three candidates are adenoviral vector-based vaccines. This review sheds light on the developmental summary of all the adenoviral vector-based vaccines that are under emergency use authorization (EUA) or in the different stages of development for COVID-19 management.

Schlagwörter

Stichwörter der Autor:innen

Ad VectorCOVIDSARS-CoV-2intramuscular vaccineintranasal vaccinenasal vaccinevariantsviral vector

Autor:innen und Institutionen

  • Department of Pharmaceutics and Pharmaceutical Technology, L. M. College of Pharmacy, Ahmedabad 380009, Gujarat, India.
  • Department of Pharmaceutical Sciences, Faculty of Science and Engineering, Dibrugarh University, Dibrugarh 786004, Assam, India.
  • Drug Product Development Laboratory, Biopharma Division, Intas Pharmaceutical Ltd., Moraiya, Ahmedabad 382213, Gujarat, India.
  • Pharmacy Section, L. M. College of Pharmacy, Ahmedabad 380009, Gujarat, India.
  • Cell and Gene Therapy Drug Product Development Laboratory, Biopharma Division, Intas Pharmaceutical Ltd., Moraiya, Ahmedabad 382213, Gujarat, India.
  • NanoBioTech Laboratory, Health Systems Engineering, Department of Environmental Engineering, Florida Polytechnic University, Lakeland, FL 33805-8531, USA.

ORCID-Profile: Vivek P Chavda, Anup Kumar, Ajeet Kaushik

Zitieren

APA

Chavda, V. P., Bezbaruah, R., Valu, D., Patel, B., Kumar, A., Prasad, S., Kakoti, B. B., Kaushik, A., & Jesawadawala, M. (2023). Adenoviral Vector-Based Vaccine Platform for COVID-19: Current Status. Vaccines, 11(2), 432. https://doi.org/10.3390/vaccines11020432

Vancouver

Chavda VP, Bezbaruah R, Valu D, Patel B, Kumar A, Prasad S, et al. Adenoviral Vector-Based Vaccine Platform for COVID-19: Current Status. Vaccines. 2023;11(2):432. doi:10.3390/vaccines11020432

BibTeX
@article{Chavda2023,
  author = {Chavda, Vivek P and Bezbaruah, Rajashri and Valu, Disha and Patel, Bindra and Kumar, Anup and Prasad, Sanjay and Kakoti, Bibhuti Bhusan and Kaushik, Ajeet and Jesawadawala, Mariya},
  title = {Adenoviral Vector-Based Vaccine Platform for COVID-19: Current Status},
  journal = {Vaccines},
  year = {2023},
  volume = {11},
  number = {2},
  pages = {432},
  doi = {10.3390/vaccines11020432}
}
Kostenlos starten →